Favipiravir + Nitazoxanide
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Oct 12, 2021 → Mar 21, 2023
NCT ID
NCT04918927About Favipiravir + Nitazoxanide
Favipiravir + Nitazoxanide is a phase 2 stage product being developed by Strides Pharma for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04918927. Target conditions include Covid19.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04918927 | Phase 2 | Completed |
Competing Products
20 competing products in Covid19